{"product_id":"veracyte-five-forces-analysis","title":"Veracyte Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVeracyte faces moderate competitive rivalry driven by niche diagnostic innovation, significant buyer scrutiny from payers and providers, supplier leverage for specialized reagents, manageable threats from substitutes and a rising risk of new entrants fueled by biotech VC—this snapshot highlights key tensions shaping its strategy. This brief preview only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Veracyte’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Specialized Sequencing Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte depends on a few specialized sequencing suppliers—Illumina accounts for an estimated \u0026gt;70% market share of short‑read NGS platforms in 2024—giving suppliers strong pricing power over platforms, consumables, and service terms.\u003c\/p\u003e\n\u003cp\u003eThese proprietary technologies are essential for Veracyte’s genomic assays, so supplier-led price increases or service-level changes can squeeze gross margins (Veracyte reported 2024 gross margin ~63%).\u003c\/p\u003e\n\u003cp\u003eSupply disruptions—chip shortages or reagent lead times—would force higher inventory costs or test delays, directly hurting revenue and margin predictability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory Materials and Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of Afirma and Decipher needs highly specific reagents and biologicals that meet CLIA and CAP standards; as of 2024 Veracyte reported \u0026gt;$480M revenue, so supply quality directly affects revenue continuity.\u003c\/p\u003e\n\u003cp\u003eSome lab consumables are commoditized, but key components (enzymes, probes, reference controls) come from a few certified vendors, raising supplier leverage and risk of price or supply shocks.\u003c\/p\u003e\n\u003cp\u003eConcentration: \u0026gt;60% of critical reagent spend tied to small vendor set, increasing bargaining power and potential margin pressure if costs rise 5–10%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Licensing Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers of patented genetic markers and bioinformatics algorithms can extract value via licensing fees and royalties—Veracyte reported R\u0026amp;D and licensing costs of $64.2 million in 2024, reflecting such dependencies. Veracyte often signs multi-year licensing deals to secure marker access and sustain diagnostic accuracy; lapses force costly redevelopment. If a patent holder raises fees or grants exclusives to rivals, Veracyte faces revenue and market-share risks tied to ~2024 revenue of $326.5 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Labor and Clinical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe global shortage of genomic experts raised average salaries for bioinformaticians and clinical geneticists by about 12% in 2024–2025, boosting Veracyte’s recruiting cost and wage burden and giving suppliers high bargaining power.\u003c\/p\u003e\n\u003cp\u003eVeracyte must offer top-tier pay, research funding, and career pathways to retain talent critical for assay development and maintain its innovation pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~12% wage inflation for genomic specialists (2024–2025)\u003c\/li\u003e\n\u003cli\u003eKey roles: bioinformaticians, genetic counselors, molecular pathologists\u003c\/li\u003e\n\u003cli\u003eHigher R\u0026amp;D compensation and funding needed to reduce turnover\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte relies on specialized couriers to keep patient samples within tight temperature ranges and fast transit; in 2024, cold-chain failures accounted for ~6%–8% of sample rejections industry-wide, raising supplier leverage.\u003c\/p\u003e\n\u003cp\u003eBecause high-integrity genomic results need premium logistics, a handful of providers control capacity and global reach, letting them push pricing and contract terms—Veracyte’s logistics spend likely represents a material operating expense share.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\n\u003cli\u003eSpecialized couriers few in number\u003c\/li\u003e\n\u003cli\u003eCold-chain failures ~6%–8% (2024 industry data)\u003c\/li\u003e\n\u003cli\u003ePremium pricing power for global reach\u003c\/li\u003e\n\u003cli\u003eLogistics = material operating cost\u003c\/li\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier power: Illumina dominance, concentrated reagents \u0026amp; wage-driven cost risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high: Illumina \u0026gt;70% short‑read share (2024), \u0026gt;60% critical reagent spend concentrated, wage inflation ~12% for genomic talent (2024–25), Veracyte 2024 revenue $480M (total reported $326.5M product revenue), gross margin ~63%, R\u0026amp;D\/licensing $64.2M—small vendor set, patented markers, and premium cold‑chain couriers create pricing and supply risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIllumina share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent concentration\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWage inflation\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~63%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/licensing\u003c\/td\u003e\n\u003ctd\u003e$64.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Veracyte, uncovering competitive drivers, buyer and supplier influence, entry barriers, substitutes, and emerging threats that shape its pricing power and market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces summary for Veracyte—quickly assess competitive intensity and strategic levers to relieve decision-making pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Payer Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge private insurers and government payers such as medicare accounted for about of veracyte revenue in giving them heavy leverage over pricing coverage decisions.\u003e\n\u003cpif major payers cut reimbursement a reduction could shrink test margins and lower veracyte gross margin of materially hurting product viability.\u003e\n\u003cppayers can also delist tests loss of coverage typically causes immediate volume drops based on industry precedents.\u003e\n\u003c\/ppayers\u003e\u003c\/pif\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital and health system consolidation formed centralized purchasing groups that control \u0026gt;50% of US hospital beds as of 2024, giving buyers strong leverage over vendors like Veracyte (NASDAQ: VCYT).\u003c\/p\u003e\n\u003cp\u003eThese large systems demand volume discounts and preferred pricing, often tying contracts to exclusive or standardized use of diagnostic platforms, pressuring Veracyte’s margins.\u003c\/p\u003e\n\u003cp\u003eProcurement power has shifted from clinicians to administrative boards, increasing requirements for pricing transparency, ROI metrics, and bundled pricing models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician Adoption and Clinical Evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhysicians drive adoption by choosing diagnostics that improve care, so Veracyte must supply strong clinical utility data—its 2024 peer-reviewed studies showing a 30–40% reduction in unnecessary surgeries for thyroid nodules are key to maintaining preference. If new evidence fails to show improved patient outcomes or cost savings versus imaging or biopsy, clinicians can revert to alternatives. Ongoing publication pace and real-world outcome data thus directly affect demand and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Direct Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cppatients are increasingly requesting specific genomic tests giving them indirect leverage over physician choices and payer coverage surveys show of oncology patients ask for testing influence test selection. veracyte must fund patient education advocacy to convert this demand into referrals reimbursement wins rise in patient-driven orders could add roughly arr based on revenue run-rates.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e42% of oncology patients request genomic tests (2024)\u003c\/li\u003e\n\u003cli\u003e28% influence clinician test choice\u003c\/li\u003e\n\u003cli\u003ePatient-driven 1% order increase ≈ $3–5M ARR (2025 run-rate)\u003c\/li\u003e\n\u003cli\u003eInvestment in advocacy raises payer approval, lowers denial rates\u003c\/li\u003e\n\n\u003c\/ppatients\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Comparative Diagnostic Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs public clinical databases grow—ClinicalTrials.gov lists 463 genomic diagnostics studies in 2024—buyers can directly compare sensitivity, specificity, and cost-effectiveness across tests, weakening Veracyte’s informational edge.\u003c\/p\u003e\n\u003cp\u003eHospitals and payers use head-to-head metrics and real-world evidence; in 2025 value-based contracts linked to diagnostic accuracy rose 22%, so procurement shifts toward higher-performing, lower-cost assays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore public studies: 463 (2024)\u003c\/li\u003e\n\u003cli\u003eValue-based contracts up 22% (2025)\u003c\/li\u003e\n\u003cli\u003eTransparency lowers information asymmetry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte at risk: payer cuts, hospital consolidation and shrinking informational edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cplarge payers private drove of veracyte revenue in giving them strong price leverage a reimbursement cut could materially compress the gross margin. consolidated hospitals control\u003e50% US beds (2024), forcing volume discounts and bundled contracts. Rising public evidence (463 genomic studies, 2024) and 22% growth in value-based diagnostic contracts (2025) reduce Veracyte’s informational edge.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer share of revenue\u003c\/td\u003e\n\u003ctd\u003e~55% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~62% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital beds via systems\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomic studies\u003c\/td\u003e\n\u003ctd\u003e463 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue-based contracts growth\u003c\/td\u003e\n\u003ctd\u003e+22% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVeracyte Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Veracyte Porter's Five Forces analysis you'll receive immediately after purchase—fully formatted, professionally written, and ready for use without placeholders or mockups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746794647929,"sku":"veracyte-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/veracyte-five-forces-analysis.png?v=1772191951","url":"https:\/\/growthsharematrix.com\/products\/veracyte-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}